AR101: eindelijk een therapie voor pinda-allergie?

Abstract

AR101: therapy for peanut allergy finally in view? Worldwide, the incidence of peanut allergy is increasing. Spontaneous tolerance only occurs in a small percentage of children who are allergic to peanuts. To date, no treatment for this potentially life-threatening condition has been proven effective. However, the recently published results of the PALISADE trial on oral immunotherapy with AR101 are promising. As AR101 has many side effects, and as it is unclear if tolerance persists after therapy is stopped, there is still a long way to go before AR101 can be added to the standard treatment for peanut allergy.